WuXi PharmaTech to Discontinue US Biologics Manufacturing Operations
WuXi PharmaTech Inc. (Shanghai, China) will discontinue its US biologics manufacturing operations as of December 31, 2008.
WuXi PharmaTech Inc. (Shanghai, China) will discontinue its US biologics manufacturing operations as of December 31, 2008. WuXi will then dedicate its Philadelphia, PA, facility to the company’s biologics testing, cell banking, and cell therapy services. Approximately 100 biologics manufacturing and supporting positions at the Philadelphia facility will be eliminated through workforce reduction and employee attrition.
Through this move, WuXi expects to record cash restructuring charges, estimated to total approximately $2.5 to $3.5 million, consisting primarily of severance and other employee-related charges to be payable over the next few months; and non-cash charges for impairment of certain fixed and intangible assets, including goodwill. WuXi is currently working with external consultants to determine an estimate for the non-cash impairment charges as a result of the restructuring.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck
May 28th 2025Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.
